Publication in Nature Immunology outlining the contribution of B cells to anticancer immunosurveillance highlights Alchemab’s capabilities and potential to develop new cancer therapies

CAMBRIDGE, England, May 14, 2024 /PRNewswire/ — Alchemab Therapeutics (Alchemab), an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announces the publication of a peer reviewed article titled “Predictability of B cell…